Table 1 Demographics of patients with pyoderma gangrenosum (PG) entered into the study.

	Infliximab group (n = 13)	Placebo group (n = 17)
Age (y)	50 (20–80)	55 (33–81)
Sex (M:F)	6:7	7:10
IBD	7/13	12/17
Crohn's disease	5/7	8/12
Ulcerative colitis	2/7	4/12
Duration of PG (weeks)*	26 (2–676)	12 (2–288)
Site of PG
Limbs	7	8
Peristomal	4	6
Perineum	2	3
DLQI score	9	8
EuroQol score	12	12
Concomitant medication
Minocycline	1	0
Prednisolone	7	5
Methotrexate	0	2
Tacrolimus paste	1	1
Topical steroid	1	2

*Median (range).

IBD, inflammatory bowel disease; DLQI, dermatology life quality index.